Ionis Pharmaceuticals Gets $28M From AstraZeneca

Carlsbad-based biopharmaceutical sdeveloper Ionis Pharmaceuticals said Friday that it has received $28M from AstraZeneca, folloing the completion of IND studies and licensing of an antisense drug for treating cancer. The company said that it is eligible to receive up to $137M more in additional development and regulatory milestone payments from AstraZenca associated with its drug, along with "low double digit" royalties from sales of the drug.